- Home
- PFBC vs TSHA Comparison
PFBC vs TSHA Comparison
Compare PFBC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFBC | TSHA |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PFBC | TSHA |
|---|---|---|
| Price | $88.60 | $4.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $102.67 | $10.56 |
| AVG Volume (30 Days) | 83.9K | ★ 2.2M |
| Earning Date | 04-24-2026 | 03-19-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $2.94 | N/A |
| Revenue Next Year | $8.31 | N/A |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $73.08 | $1.13 |
| 52 Week High | $103.05 | $6.02 |
Technical Indicators
Market Signals| Indicator | PFBC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 48.35 |
| Support Level | $88.78 | $4.39 |
| Resistance Level | $93.52 | $5.16 |
| Average True Range (ATR) | 2.40 | 0.20 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 62.20 | 62.65 |
Price Performance
Historical ComparisonAbout PFBC Preferred Bank
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.